TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05579028

Intervention type: DIETARY_SUPPLEMENT
Intervention: Nutridrink ONS 200 ml
Description: Nutridrink is a high-protein, high-calorie formula for the specialized nutrition of patients with or at risk of malnutrition. The product can be used as an additional or sole source of nutrition
Study: NCT01257178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2624803
Description: Administered orally
Study: NCT03635541

Intervention type: OTHER
Intervention: observational group of NAFLD
Description: there's no intervention for patients for it is a observational study
Study: NCT02319018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV
Study: NCT02760680

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: WatchPAT 200 (TM)
Description: The WatchPAT 200 (TM) is a wrist worn diagnostic device for detecting SDB. Its main part is the measurement of the peripheral arterial tone (PAT) via a plethysmographic based finger-mounted probe. It can measure the level of sympathetic activation of the autonomic nervous system. Pulse rate, oxygen saturation and snoring/body position levels are calculated, too. A software program (zzzPAT (TM)) with a special algorithm analyzes the raw data and creates a sleep report. Therefore the property of the WatchPAT 200 (TM) proclaims that the WatchPAT 200 (TM) can detect sleep events and SDB.
Study: NCT01257178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2624803
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2624803
Description: Administered orally
Study: NCT02760680

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: WatchPAT 200 (TM)
Description: The WatchPAT 200 (TM) is a wrist worn diagnostic device for detecting SDB. Its main part is the measurement of the peripheral arterial tone (PAT) via a plethysmographic based finger-mounted probe. It can measure the level of sympathetic activation of the autonomic nervous system. Pulse rate, oxygen saturation and snoring/body position levels are calculated, too. A software program (zzzPAT (TM)) with a special algorithm analyzes the raw data and creates a sleep report. Therefore the property of the WatchPAT 200 (TM) proclaims that the WatchPAT 200 (TM) can detect sleep events and SDB.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Polysomnography
Description: The PSG is known as the Gold Standard for detecting SDB: experienced sleep physicians and technicians score events (apnea/hypopnea) using current AASM Guidelines.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Polysomnography
Description: The PSG is known as the Gold Standard for detecting SDB: experienced sleep physicians and technicians score events (apnea/hypopnea) using current AASM Guidelines.
Study: NCT03717220

Intervention type: PROCEDURE
Group type: OTHER
Intervention: flap transferring
Description: we use regional dorsal digital flaps for simultaneous reconstruction of multiple-digit soft-tissue defects
Study: NCT00731094

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expert system-based physical activity counseling
Description: The intervention included 14 mailings to participants that involved completion of physical activity questionnaires printed on forms that were scanned into a computerized expert system program to generate individually-tailored feedback messages and related manuals based on the Stages of Motivational Readiness for Change Model. Newsletters providing additional support and suggestions for increasing physical activity were also part of the mailing program.
Study: NCT00462501

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Study: NCT01210898

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted seasonal influenza vaccine
Description: Full or half dose of adjuvanted seasonal influenza vaccine; Full or half dose of unadjuvanted seasonal influenza vaccine
Study: NCT00462501

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT04427423

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical therapy treatment
Description: the experimental group received positional distraction plus stabilization exercises and the control group received stabilization exercises only.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physical therapy treatment
Description: the experimental group received positional distraction plus stabilization exercises and the control group received stabilization exercises only.
Study: NCT00556972

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fecal Incontinence Management System
Description: The device is intended to remedy fecal incontinence.
Study: NCT03158454

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Capsula Closure
Description: The capsular closure is performed with a minimum of two vicryl # 2 resorbable sutures

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Non-Capsula Closure
Description: No capsular closure procedure is performed.
Study: NCT01210898

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted seasonal influenza vaccine
Description: Full or half dose of adjuvanted seasonal influenza vaccine; Full or half dose of unadjuvanted seasonal influenza vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted seasonal influenza vaccine
Description: Full or half dose of adjuvanted seasonal influenza vaccine; Full or half dose of unadjuvanted seasonal influenza vaccine
Study: NCT02620826

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Indirect pulp therapy
Description: Decayed dentin is lined with a resin-modified glass ionomer (Vitrebond Plus)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulpotomy
Description: A cervical pulpotomy is done and the radicular pulp is lined with Mineral Trioxide Aggregate
Study: NCT03004898

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: multidisciplinary renal education
Description: multidisciplinary CKD care involving case management nurse, dietitian, social worker, pharmacists.
Study: NCT01970020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-38518168
Description: Following an at least 10-hour overnight fast, participants will receive a single dose containing 30 mg of 14C JNJ-38518168 given as an oral solution on Day 1
Study: NCT00938366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Subjects will receive two single doses of 10 mg cladribine orally in either first or second intervention period followed by a washout period of 10-25 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Subjects will receive two single doses of 10 mg cladribine orally in either first or second intervention period followed by a washout period of 10-25 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Description: Subjects will receive a pantoprazole 40 mg orally for 2 consecutive days either in first or second intervention period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Description: Subjects will receive a pantoprazole 40 mg orally for 2 consecutive days either in first or second intervention period.
Study: NCT01210898

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted seasonal influenza vaccine
Description: Full or half dose of adjuvanted seasonal influenza vaccine; Full or half dose of unadjuvanted seasonal influenza vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted seasonal influenza vaccine
Description: Full or half dose of adjuvanted seasonal influenza vaccine; Full or half dose of unadjuvanted seasonal influenza vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted seasonal influenza vaccine
Description: Full or half dose of adjuvanted seasonal influenza vaccine; Full or half dose of unadjuvanted seasonal influenza vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted seasonal influenza vaccine
Description: Full or half dose of adjuvanted seasonal influenza vaccine; Full or half dose of unadjuvanted seasonal influenza vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted seasonal influenza vaccine
Description: Full or half dose of adjuvanted seasonal influenza vaccine; Full or half dose of unadjuvanted seasonal influenza vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted seasonal influenza vaccine
Description: Full or half dose of adjuvanted seasonal influenza vaccine; Full or half dose of unadjuvanted seasonal influenza vaccine
Study: NCT04516109

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Modified hip capsule side fixed slotted cannula
Description: Modified hip capsule side fixed slotted cannula used during surgery to allow for continued access to the hip joint.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Modified hip capsule side fixed slotted cannula
Description: Modified hip capsule side fixed slotted cannula used during surgery to allow for continued access to the hip joint.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Modified bone graft delivery tool set
Description: Modified bone graft delivery tool set for grafting subchrondral cysts arthroscopically during hip arthroscopy procedure.
Study: NCT04789876

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phosphate mobile app
Description: The phosphate mobile app has the features of i) matching phosphate binder with dietary phosphate intake, ii) educational videos of phosphate management, iii) food database with local food items, iv) record-keeping and goal setting.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: One-off dietary counselling with a phosphate booklet
Description: One-off 45-minute dietary counselling delivered by a dietitian at the baseline of the study. Patients received a complimentary phosphate booklet after the counselling session. The phosphate booklet contains similar educational information as per the phosphate mobile app excluding the matching of phosphate binder with dietary phosphate information.
Study: NCT01685697

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mask ventilation with a Laerdal face mask
Description: Mask leak will be measured using a respiratory function monitor. Mask ventilation will be analyzed over a period of 5 minutes. The mean mask leak will be compared to the intervention group.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mask ventilation with a F&P face mask
Description: Mask leak will be measured using a respiratory function monitor. Mask ventilation will be analyzed over a period of 5 minutes. The mean mask leak will be compared to the control group.
Study: NCT01461707

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile phone-based physical activity
Description: Participants will receive the mobile phone-based physical activity program using the trial app.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Activity monitor
Description: Participants will receive an activity monitor

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Activity monitor
Description: Participants will receive an activity monitor
Study: NCT04459871

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant human Thrombin(CHO cell)
Description: 2 rhThrombin, dissolved in 5mL sterile saline and mixed, the final solution contains 1000IU/mL rhThrombin solution (clear and transparent liquid).

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo, dissolved in 5mL sterile saline and mixed, the final solution contains 1000IU/mL rhThrombin solution (clear and transparent liquid).
Study: NCT00535002

Intervention type: DRUG
Group type: OTHER
Intervention: Yohimbine
Description: Participants were pre-treated with either yohimbine or placebo.

Intervention type: DRUG
Group type: OTHER
Intervention: Yohimbine
Description: Participants were pre-treated with either yohimbine or placebo.

Intervention type: DRUG
Group type: OTHER
Intervention: Yohimbine
Description: Participants were pre-treated with either yohimbine or placebo.

Intervention type: DRUG
Group type: OTHER
Intervention: Yohimbine
Description: Participants were pre-treated with either yohimbine or placebo.

Intervention type: DRUG
Group type: OTHER
Intervention: Yohimbine
Description: Participants were pre-treated with either yohimbine or placebo.

Intervention type: DRUG
Group type: OTHER
Intervention: Yohimbine
Description: Participants were pre-treated with either yohimbine or placebo.

Intervention type: DRUG
Group type: OTHER
Intervention: Yohimbine
Description: Participants were pre-treated with either yohimbine or placebo.

Intervention type: DRUG
Group type: OTHER
Intervention: Yohimbine
Description: Participants were pre-treated with either yohimbine or placebo.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Study: NCT00607282

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Udenafil
Description: oral administration of Udenafil, prn(2hours before anticipated intercourse, 8 times/months)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Udenafil
Description: oral administration of Udenafil, prn(2hours before anticipated intercourse, 8 times/months)
Study: NCT04022135

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Folic acid
Description: Participants will supplement with 0.6mg/day for 16 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: (6S)-5-methyltetrahydrofolic acid
Description: Participants will supplement with 0.625mg/day for 16 weeks.
Study: NCT02850003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-120 Gel
Description: Gel
Study: NCT04566237

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Objective Scatter Index (OSI)
Description: On Optical Quality Analysis System (OQAS) device. At Inclusion, 3 months, 12 months and 24 months after vitrectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Average Lens Density (ALD)
Description: on IOLMaster® 700 device. At Inclusion, 3 months, 12 months and 24 months after vitrectomy
Study: NCT04052542

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional online continuing education
Description: 30-minute, online, interactive, educational video describing the benefits of preventive post-extubation NIV, the indications and contraindications for preventive post-extubation NIV, and the value of working together as an interprofessional ICU team when implementing preventive post-extubation NIV

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interprofessional education
Description: One-time, 90-120-minute, in-person, interprofessional educational workshop consisting of a 30-minute didactic session and a 60-90-minute small group session

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Just-in-time education
Description: Just-in-time, point-of-care education provided by trained advanced practice providers who will be on-hand in the study ICU, where they will deliver the education at the bedside during rounds when a patient meets criteria for preventive post-extubation NIV
Study: NCT00535002

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Study: NCT02989753

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VAL070-A
Description: After randomization (V1 visit), 8 capsules per day of VAL070-A during 12 weeks (from visit V1 to visit V2). They will consume 3 capsules at the beginning of their breakfast, 2 capsules at the beginning of their lunch and 3 capsules at the beginning of their dinner.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VAL070-B
Description: After randomization (V1 visit), 8 capsules per day of VAL070-B during 12 weeks (from visit V1 to visit V2). They will consume 3 capsules at the beginning of their breakfast, 2 capsules at the beginning of their lunch and 3 capsules at the beginning of their dinner.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After randomization (V1 visit), 8 capsules per day of placebo during 12 weeks (from visit V1 to visit V2). They will consume 3 capsules at the beginning of their breakfast, 2 capsules at the beginning of their lunch and 3 capsules at the beginning of their dinner.
Study: NCT03798327

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Palliative Care
Description: Patients/caregivers will be cared for by an interdisciplinary team that includes a social worker, nurse, community health worker, nurse practitioner, and physician.
Study: NCT01339390

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MOVE OUT
Description: The MOVE OUT intervention builds on the high quality information provided by the nationally-developed MOVE program by adding 1) peer support; 2) convenient local access to educational sessions, which allows the material to be delivered in smaller, more easily retained aliquots; 3) convenient local exercise opportunities; and 4) open-ended availability of both education and exercise support.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MOVE!
Description: As part of routine care at the ZVAMC, all patients who are eligible for the present study are identified by a clinical reminder. This reminder prompts the PCP to determine if the person would benefit from a weight loss program, and to refer them to MOVE if they and the patient agree that it would be beneficial. The MOVE program in Milwaukee can be tailored by the patient and PCP, but includes dietitian assessment, education, weekly weigh-ins, follow-up classes, and exercise programs.
Study: NCT01062529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatostatin
Description: 4 h of 150 microgram infusion
Study: NCT03445936

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Parietene Macro
Description: Parietene Macro is placed and sutured on retro muscular space on closed posterior rectus sheath to prevent incisional hernia.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Permacol
Description: Permacol biologic implant is placed and sutured on retro muscular space on closed posterior rectus sheath to prevent incisional hernia.
Study: NCT00509223

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positive Airway Pressure therapy
Description: Positive Airway Pressure (PAP) therapy initiated at Randomization and continued through the entire study duration (6 months), with instructions for use on a daily basis, during periods of sleep.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle counseling
Description: Lifestyle counseling: All subjects were counseled regarding adopting a healthy lifestyle and advised on the Heart Foundation, National Health and Medical Research Council, and American Diabetes Association nutrition and exercise recommendations.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle counseling
Description: Lifestyle counseling: All subjects were counseled regarding adopting a healthy lifestyle and advised on the Heart Foundation, National Health and Medical Research Council, and American Diabetes Association nutrition and exercise recommendations.
Study: NCT02007824

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ULSD-12D
Description: wound cleansing and debridement using ULSD-12D

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SONOCA-180
Description: wound cleansing and debridement using SONOCA-180
Study: NCT03678909

Intervention type: PROCEDURE
Intervention: Norwood Palliation / DKS / Damus-Kaye-Stansel procedure
Description: Norwood Palliation / DKS / Damus-Kaye-Stansel procedure
Study: NCT01821131

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: muffin

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: muffin

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: muffin
Study: NCT03803371

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ultracet Tablets
Description: Ultracet tablet (Janssen Cilag Farmacêutica Ltda) equivalent to Tramadol hydrochloride 37.5 mg/Paracetamol 325 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol hydrochloride 37.5 mg/Paracetamol 325 mg tablets - tablet (Pfizer)
Description: Tramadol hydrochloride 37.5 mg/Paracetamol 325 mg tablets (Pfizer)
Study: NCT03329404

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mirasol Red Blood Cells (MIR RBCs)
Description: Mirasol Red Blood Cells (MIR RBCs) derived from Mirasol-treated WB; WB will be Mirasol treated, centfifuged and leukoreduced and the derived RBCs will be stored before transfusion for up to 21 days and transfused according to the patient's transfusion schedule.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Reference Red Blood Cells (REF RBCs)
Description: Reference Red Blood Cells (REF RBCs) will be acquired from routine use inventory and transfused according to the patient's transfusion schedule.
Study: NCT01959282

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54781532 25 mg once daily
Description: Participants will receive 25 mg of JNJ-54781532 once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54781532 75 mg once daily
Description: Participants will receive 75 mg of JNJ-54781532 once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54781532 150 mg once daily
Description: Participants will receive 150 mg of JNJ-54781532 once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: JNJ-54781532 150 mg once daily
Description: Participants will receive 150 mg of JNJ-54781532 once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54781532 75 mg twice daily
Description: Participants will receive 75 mg of JNJ-54781532 twice daily